Now showing items 1-10 of 10

    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2002-04-16)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1999-06-08)
      Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for example, 0.1 to 1.5 IU per ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1985-02-05)
      The appetite of a warm-blooded vertebrate can be regulated by administering to the vertebrate a biological active fraction of interferon in an amount effective to modulate the vertebrate's food intake or efficiency in ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1989-04-11)
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-12-08)
      Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-10-06)
      Bacterial infections are treated by the administration of alpha-interferon at a dosage of from about 0.1 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1999-03-16)
      Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. ...
    • Cummins, Joseph M., Jr. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1991-05-28)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-10-20)
      Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and ...
    • Cummins, Joseph M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1998-11-03)
      Viral infections are treated by the administration of alpha-interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The ...